Ultragenyx Pharmaceutical
RARE
159 hedge funds and large institutions have $2.56B invested in Ultragenyx Pharmaceutical in 2017 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 81 increasing their positions, 40 reducing their positions, and 19 closing their positions.
225% more call options, than puts
Call options by funds: $15.7M | Put options by funds: $4.83M
103% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 40
0.01% less ownership
Funds ownership: 97.59% → 97.59% (-0.01%)
4% less funds holding
Funds holding: 165 → 159 (-6)
7% less capital invested
Capital invested by funds: $2.76B → $2.56B (-$201M)
26% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 19
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$40.1M |
| 2 |
BlackRock
New York
|
+$19.9M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$19.7M |
| 4 |
State Street
Boston,
Massachusetts
|
+$16.3M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$12.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$139M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$18.2M |
| 3 |
PC
Polar Capital
London,
United Kingdom
|
-$7.73M |
| 4 |
CGT
Capital Guardian Trust
Los Angeles,
California
|
-$6.73M |
| 5 |
QIM
Quantitative Investment Management
Charlottesville,
Virginia
|
-$5.67M |
RARE Hedge Fund Activity: Q2 2017 in Review
159 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q2 2017, worth a combined $2.56B — down 7.3% from $2.76B a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of RARE and 14 opened new positions — a net loss of 5 holders — while 40 trimmed existing stakes and 81 added.
The largest buyer was Wellington Management Group, adding an estimated $40.1M. The largest seller was Fidelity Investments, cutting an estimated $139M.
- 159 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q2 2017, down from 165 in Q1 2017.
- Funds reported $2.56B of Ultragenyx Pharmaceutical stock for Q2 2017, down 7.3% quarter-over-quarter.
- 14 funds opened new Ultragenyx Pharmaceutical positions in Q2 2017 and 19 closed out, a net change of -5 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q2 2017 was Wellington Management Group, an estimated $40.1M added.
- The largest Ultragenyx Pharmaceutical seller in Q2 2017 was Fidelity Investments, an estimated $139M sold.
Based on aggregated 13F filings for Q2 2017.